

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Simvastatin versus Atorvastatin in the treatment of mild to moderate depression in post CABG patients: a double blind randomized clinical trial

Protocol summary

s.akhond@sina.tums.ac.ir

Summary

Patients will be randomized into two 25 participants groups according to Random Permuted Block. One group will receive 20 mg Simvastatin per day for 6 weeks and the other group will receive 20 mg Atorvastatin per day for 6 weeks. All participants will be evaluated by HAM-D questionnaire at weeks 0, 2, 4, and 6. Side effects of the drugs will be checked at weeks 1, 2, 4, and 6. At the end of the study the effects and the side effects of the both drugs will be compared. At the beginning of the study, at week 2 and at week 6, liver enzymes (ALT, AST, ALK, and Bilirubin) and lipids (TG, Total Cholesterol, LDL, and HDL) will be checked.

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2014-10-28, 1393/08/06

Expected recruitment end date

2014-12-27, 1393/10/06

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201410271556N68**

Registration date: **2014-10-28, 1393/08/06**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2014-10-28, 1393/08/06

Registrant information

Name

Shahin Akhondzadeh

Name of organization / entity

Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 2222

Email address

Scientific title

Simvastatin versus Atorvastatin in the treatment of mild to moderate depression in post CABG patients: a double blind randomized clinical trial

Public title

Comparison between the effect of Simvastatin and Atorvastatin in controlling post cardiac surgery depression.

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: 1. Patients who have undergone coronary bypass surgery. 2. Patients who based on DSM-IV have major depression and based Hamilton rating scale for depression (Ham-D 17 items) their score is => 18. 3. No psychiatric symptoms 4. Not receiving psychotropic drugs 5. Not receiving antidepressants during the last month 6. Do not receiving ECT during the last two months 7. No thyroid problem 8. Age between 15 and 80 years 9. No liver dysfunction 10. No Muscular disorders 11. Not receiving other antilipid drugs 12. No hypersensitivity to statins 13. LDL => 80 14. Liver enzymes not being elevated at the time of recruitment

15. No life threatening disease 16. No neurological disorders 17. Not being pregnant 18. No breast feeding 19. Giving informed consent Exclusion criteria: 1. Existing other disorders rather than depression, including Bipolar disorders, Schizophrenia, and other psychotic disorders 2. History of drug abuse or dependency within the last three months 3. Probability of suicide or its tendency during the last year 4. Women who are going to be pregnant within the next few months 5. Women who use OCP for pregnancy prevention 6. Patients who have received antidepressants during the last month 7. Patients who have received ECT within the last two months 8. Patients who need un-usual psychiatric treatments 9. Patients with liver dysfunction 10. Muscular disorders 11. Receiving other antilipid drugs 12. Hypersensitivity to statins 13. LDL < 80 14. Elevated liver enzymes at the time of recruitment 15. Life threatening diseases 16. Neurological diseases

Age

From **15 years** old to **80 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Tehran University of Medical Sciences Ethics Committee

Street address

Tehran University of Medical Sciences, Keshavarz Boulevard, Ghods Street

City

Tehran

Postal code**Approval date**

2012-10-30, 1391/08/09

Ethics committee reference number

19165

Health conditions studied**1****Description of health condition studied**

Depression

ICD-10 code

F32.1

ICD-10 code description

Moderate depressive episode

Primary outcomes**1****Description**

Depression

Timepoint

At the starting time, two weeks after intervention, four weeks after intervention, and six weeks after intervention

Method of measurement

Hamilton Depression Questionnaire

Secondary outcomes**1****Description**

Drugs side effects

Timepoint

First week after starting the study, second week after starting the study, fourth week after starting the study, and sixth week after starting the study

Method of measurement

Drug side effects checklist

Intervention groups**1****Description**

Second group will receive 20 mg Atorvastatin per day for 6 weeks.

Category

Treatment - Drugs

2**Description**

First group will receive 20 mg Simvastatin per day for 6 weeks.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center**

Name of recruitment center

Tehran Heart Center
Full name of responsible person
Dr. Seyed Hesameddin Abbasi
Street address
Tehran Heart Center, North Kargar Street
City
Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr. Masoud Younesian
Street address
Tehran University of Medical Sciences, Ghods Street,
Keshavarz Boulevard
City
Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity
Tehran Heart Center
Full name of responsible person
Dr. Seyed Hesameddin Abbasi
Position
PhD student in Epidemiology
Other areas of specialty/work
Street address
Tehran Heart Center, North Kargar Street
City
Tehran
Postal code
1411713138
Phone
+98 21 8802 9720
Fax
Email
abbasi.hesam@gmail.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Faculty of Medicine, Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
Faculty of Medicine, Tehran University of Medical Sciences, Poursina Street
City
Tehran
Postal code
Phone
+98 21 6641 8466
Fax
Email
s.akhond@neda.net
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Tehran Heart Center
Full name of responsible person
Dr. Seyed Hesameddin Abbasi
Position
PhD student in Epidemiology
Other areas of specialty/work
Street address
Tehran Heart Center, North Kargar Street
City
Tehran
Postal code
1411713138
Phone
+98 21 8802 9720
Fax
Email
abbasi.hesam@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code
empty

Data Dictionary
empty